ZNF726 Inhibitors
The chemical class of ZNF726 inhibitors encompasses a diverse array of small molecules targeting various signaling pathways implicated in cellular proliferation, survival, and transcriptional regulation. These inhibitors exert their effects through different mechanisms, including modulation of kinase activity, inhibition of transcription factors, and interference with protein-protein interactions. For instance, inhibitors like Ruxolitinib and Axitinib target Janus kinase (JAK) and vascular endothelial growth factor receptors (VEGFRs), respectively, thereby disrupting downstream signaling pathways involved in cell proliferation and survival. Similarly, compounds like TAK-243 and 17-AAG inhibit ubiquitin-specific protease 10 (USP10) and heat shock protein 90 (Hsp90), respectively, leading to alterations in protein stability and degradation processes that may indirectly affect ZNF726 expression levels.
Other inhibitors such as XAV939 and BAY 11-7082 modulate the activity of key transcriptional regulators like tankyrase and nuclear factor-kappa B (NF-κB), respectively, impacting the transcriptional output of genes involved in cellular proliferation and survival. Furthermore, small molecule inhibitors like SB202190 and NVP-BKM120 target intracellular signaling cascades such as p38 mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K), respectively, which are critical for cell growth and proliferation. By interfering with these signaling pathways, these inhibitors can indirectly influence ZNF726 expression by altering downstream transcriptional activities. Overall, the chemical class of ZNF726 inhibitors offers a powerful toolkit for dissecting the molecular mechanisms underlying ZNF726 function and exploring its ability as a target in various diseases, including cancer.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV939 is a tankyrase inhibitor that disrupts Wnt/β-catenin signaling pathway, which plays a crucial role in cell proliferation and differentiation. By inhibiting tankyrase activity, XAV939 can potentially suppress the expression of ZNF726, as it is involved in Wnt/β-catenin-mediated transcriptional regulation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks JAK/STAT signaling, which regulates cell growth, proliferation, and differentiation. Inhibition of JAK by Ruxolitinib can indirectly influence ZNF726 expression by modulating downstream transcriptional activities involved in cell proliferation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a key component of the Ras/Raf/MEK/ERK signaling pathway. By inhibiting MEK activity, Trametinib can potentially modulate downstream signaling cascades involved in cell proliferation and differentiation, thereby influencing ZNF726 expression. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG is an inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone involved in the folding and stabilization of client proteins, including oncogenic signaling molecules. Inhibition of Hsp90 by 17-AAG can potentially disrupt ZNF726 function by promoting its degradation and reducing its stability. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is an inhibitor of nuclear factor-kappa B (NF-κB) activation, which regulates cell survival, inflammation, and immune responses. Inhibition of NF-κB by BAY 11-7082 can indirectly impact ZNF726 expression by modulating the transcriptional regulation of target genes involved in cell proliferation. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
SB202190 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), a key regulator of cellular stress responses and inflammation. By blocking p38 MAPK signaling, SB202190 can potentially influence ZNF726 expression indirectly through its effects on downstream transcriptional activities. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
NVP-BKM120 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), a key regulator of cell growth, proliferation, and survival. Inhibition of PI3K by NVP-BKM120 can indirectly impact ZNF726 expression by modulating downstream signaling pathways involved in cellular growth and proliferation. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is involved in the Ras/Raf/MEK/ERK signaling pathway. By inhibiting MEK activity, Selumetinib can potentially modulate downstream signaling cascades involved in cell proliferation and differentiation, thereby influencing ZNF726 expression. | ||||||